Cargando…

TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer

Pancreatic cancer is one of the most malignant tumors worldwide. DNA replication plays a critical role in the occurrence and development of pancreatic cancer. TYMS encodes thymidylate synthase, which is important for DNA synthesis. The TYMS gene has been assessed in some tumors. However, the specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Zhuo, Jiao, Yan, Li, Yanqing, Ji, Bai, Jia, Baoxing, Liu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940182/
https://www.ncbi.nlm.nih.gov/pubmed/31861032
http://dx.doi.org/10.1097/MD.0000000000018487
_version_ 1783484313911689216
author Fu, Zhuo
Jiao, Yan
Li, Yanqing
Ji, Bai
Jia, Baoxing
Liu, Bin
author_facet Fu, Zhuo
Jiao, Yan
Li, Yanqing
Ji, Bai
Jia, Baoxing
Liu, Bin
author_sort Fu, Zhuo
collection PubMed
description Pancreatic cancer is one of the most malignant tumors worldwide. DNA replication plays a critical role in the occurrence and development of pancreatic cancer. TYMS encodes thymidylate synthase, which is important for DNA synthesis. The TYMS gene has been assessed in some tumors. However, the specific role of TYMS in pancreatic cancer has not been identified. This study was designed to clarify the diagnostic and prognostic significance of TYMS in pancreatic cancer. The Cancer Genome Atlas (TCGA) database was used to compare TYMS expression in pancreatic cancer, and ROC curve analysis was used to investigate its diagnostic value. The correlation between clinical characteristics and TYMS expression was analyzed, and the prognostic value of TYMS expression in the patients with pancreatic cancer was assessed by Kaplan–Meier curves and Cox analysis. TYMS was upregulated in pancreatic cancer and associated with poor overall survival (OS) and recurrence-free survival (RFS). Univariate and multivariate survival analysis demonstrated that TYMS is an independent risk factor for OS and RFS in patients with pancreatic cancer. The upregulation of TYMS in pancreatic cancer leads to unfavorable OS and RFS in patients, and represents a diagnostic and prognostic biomarker for patients with pancreatic cancer.
format Online
Article
Text
id pubmed-6940182
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-69401822020-01-31 TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer Fu, Zhuo Jiao, Yan Li, Yanqing Ji, Bai Jia, Baoxing Liu, Bin Medicine (Baltimore) 4500 Pancreatic cancer is one of the most malignant tumors worldwide. DNA replication plays a critical role in the occurrence and development of pancreatic cancer. TYMS encodes thymidylate synthase, which is important for DNA synthesis. The TYMS gene has been assessed in some tumors. However, the specific role of TYMS in pancreatic cancer has not been identified. This study was designed to clarify the diagnostic and prognostic significance of TYMS in pancreatic cancer. The Cancer Genome Atlas (TCGA) database was used to compare TYMS expression in pancreatic cancer, and ROC curve analysis was used to investigate its diagnostic value. The correlation between clinical characteristics and TYMS expression was analyzed, and the prognostic value of TYMS expression in the patients with pancreatic cancer was assessed by Kaplan–Meier curves and Cox analysis. TYMS was upregulated in pancreatic cancer and associated with poor overall survival (OS) and recurrence-free survival (RFS). Univariate and multivariate survival analysis demonstrated that TYMS is an independent risk factor for OS and RFS in patients with pancreatic cancer. The upregulation of TYMS in pancreatic cancer leads to unfavorable OS and RFS in patients, and represents a diagnostic and prognostic biomarker for patients with pancreatic cancer. Wolters Kluwer Health 2019-12-20 /pmc/articles/PMC6940182/ /pubmed/31861032 http://dx.doi.org/10.1097/MD.0000000000018487 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4500
Fu, Zhuo
Jiao, Yan
Li, Yanqing
Ji, Bai
Jia, Baoxing
Liu, Bin
TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
title TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
title_full TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
title_fullStr TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
title_full_unstemmed TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
title_short TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
title_sort tyms presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940182/
https://www.ncbi.nlm.nih.gov/pubmed/31861032
http://dx.doi.org/10.1097/MD.0000000000018487
work_keys_str_mv AT fuzhuo tymspresentsanovelbiomarkerfordiagnosisandprognosisinpatientswithpancreaticcancer
AT jiaoyan tymspresentsanovelbiomarkerfordiagnosisandprognosisinpatientswithpancreaticcancer
AT liyanqing tymspresentsanovelbiomarkerfordiagnosisandprognosisinpatientswithpancreaticcancer
AT jibai tymspresentsanovelbiomarkerfordiagnosisandprognosisinpatientswithpancreaticcancer
AT jiabaoxing tymspresentsanovelbiomarkerfordiagnosisandprognosisinpatientswithpancreaticcancer
AT liubin tymspresentsanovelbiomarkerfordiagnosisandprognosisinpatientswithpancreaticcancer